Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Gaisler-Salomon, Inna
Miller, Gretchen M
Chuhma, Nao
Lee, Sooyeon
Zhang, Hong
Ghoddoussi, Farhad
Lewandowski, Nicole
Fairhurst, Stephen
Wang, Yvonne
Conjard-Duplany, Agnès
Masson, Justine
Balsam, Peter
Hen, René
Arancio, Ottavio
Galloway, Matthew P
Moore, Holly M
Small, Scott A
and
Rayport, Stephen
2009.
Glutaminase-Deficient Mice Display Hippocampal Hypoactivity, Insensitivity to Pro-Psychotic Drugs and Potentiated Latent Inhibition: Relevance to Schizophrenia.
Neuropsychopharmacology,
Vol. 34,
Issue. 10,
p.
2305.
Collip, D.
Oorschot, M.
Thewissen, V.
Van Os, J.
Bentall, R.
and
Myin-Germeys, I.
2011.
Social world interactions: how company connects to paranoia.
Psychological Medicine,
Vol. 41,
Issue. 5,
p.
911.
Esslinger, Christine
Englisch, Susanne
Inta, Dragos
Rausch, Franziska
Schirmbeck, Frederike
Mier, Daniela
Kirsch, Peter
Meyer-Lindenberg, Andreas
and
Zink, Mathias
2012.
Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients.
Schizophrenia Research,
Vol. 140,
Issue. 1-3,
p.
114.
Esslinger, Christine
Braun, Urs
Schirmbeck, Frederike
Santos, Andreia
Meyer-Lindenberg, Andreas
Zink, Mathias
Kirsch, Peter
and
Harrison, Ben J.
2013.
Activation of Midbrain and Ventral Striatal Regions Implicates Salience Processing during a Modified Beads Task.
PLoS ONE,
Vol. 8,
Issue. 3,
p.
e58536.
Thase, Michael E.
Kingdon, David
and
Turkington, Douglas
2014.
The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.
World Psychiatry,
Vol. 13,
Issue. 3,
p.
244.
Klosterkötter, Joachim
2014.
The usefulness for indicated prevention of severe mental disorders should play a central part in the further development of CBT.
World Psychiatry,
Vol. 13,
Issue. 3,
p.
259.
Bhattacharyya, Sagnik
Falkenberg, Irina
Martin-Santos, Rocio
Atakan, Zerrin
Crippa, Jose A
Giampietro, Vincent
Brammer, Mick
and
McGuire, Philip
2015.
Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience.
Neuropsychopharmacology,
Vol. 40,
Issue. 6,
p.
1343.
Smieskova, Renata
Roiser, Jonathan P.
Chaddock, Christopher A.
Schmidt, André
Harrisberger, Fabienne
Bendfeldt, Kerstin
Simon, Andor
Walter, Anna
Fusar-Poli, Paolo
McGuire, Philip K.
Lang, Undine E.
Riecher-Rössler, Anita
and
Borgwardt, Stefan
2015.
Modulation of motivational salience processing during the early stages of psychosis.
Schizophrenia Research,
Vol. 166,
Issue. 1-3,
p.
17.
Walter, Anna
Suenderhauf, Claudia
Smieskova, Renata
Lenz, Claudia
Harrisberger, Fabienne
Schmidt, André
Vogel, Tobias
Lang, Undine E.
Riecher-Rössler, Anita
Eckert, Anne
and
Borgwardt, Stefan
2016.
Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms.
Frontiers in Psychiatry,
Vol. 7,
Issue. ,
Blessing, William W.
Blessing, Esther M.
Mohammed, Mazher
and
Ootsuka, Youichirou
2017.
Clozapine, chlorpromazine and risperidone dose-dependently reduce emotional hyperthermia, a biological marker of salience.
Psychopharmacology,
Vol. 234,
Issue. 21,
p.
3259.
Prom-Wormley, E.
Langi, G.
Clifford, J.
and
Real, J.
2017.
Addictive Substances and Neurological Disease.
p.
251.
Knolle, Franziska
Ermakova, Anna O
Justicia, Azucena
Fletcher, Paul C
Bunzeck, Nico
Düzel, Emrah
and
Murray, Graham K
2018.
Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study.
Translational Psychiatry,
Vol. 8,
Issue. 1,
Grimm, Oliver
Löffler, Martin
Kamping, Sandra
Hartmann, Aljoscha
Rohleder, Cathrin
Leweke, Markus
and
Flor, Herta
2018.
Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity.
European Neuropsychopharmacology,
Vol. 28,
Issue. 7,
p.
841.
Wijayendran, Surapi Bhairavi
O’Neill, Aisling
and
Bhattacharyya, Sagnik
2018.
The effects of cannabis use on salience attribution: a systematic review.
Acta Neuropsychiatrica,
Vol. 30,
Issue. 1,
p.
43.
Horga, Guillermo
and
Abi-Dargham, Anissa
2019.
An integrative framework for perceptual disturbances in psychosis.
Nature Reviews Neuroscience,
Vol. 20,
Issue. 12,
p.
763.
Gross, Madeleine E.
Araujo, Draulio B.
Zedelius, Claire M.
and
Schooler, Jonathan W.
2019.
Is perception the missing link between creativity, curiosity and schizotypy? Evidence from spontaneous eye-movements and responses to auditory oddball stimuli.
NeuroImage,
Vol. 202,
Issue. ,
p.
116125.
Lamontagne, Steven J.
and
Olmstead, Mary C.
2019.
Animal models in addiction research: A dimensional approach.
Neuroscience & Biobehavioral Reviews,
Vol. 106,
Issue. ,
p.
91.
Crespi, Bernard J.
2020.
The Cambridge Handbook of the Imagination.
p.
760.
Ballerini, Andrea
Tortorelli, Marta
Marino, Paolo
Appignanesi, Cristina
Baschirotto, Cinzia
Mallardo, Luca
Tofani, Tommaso
Pietrini, Francesco
D’Anna, Giulio
Rossi, Andrea
Ricca, Valdo
and
Santella, Marina
2022.
Aberrant salience relationship with first rank symptoms.
Annals of General Psychiatry,
Vol. 21,
Issue. 1,
All models are wrong, but some are useful (Box, Reference Box, Launer and Wilkinson1979)
Psychosis remains one of the most distressing, yet intriguing, human conditions. The profession of psychiatry grew up in asylums trying to grapple with psychosis over a century ago. How best to understand and treat psychosis is still an ongoing academic challenge. At one level psychosis is a behavioural phenomenon. At another it is tied to the brain, its chemistry and circuits. Thus, any complete explanation of psychosis will have to try and link explanations at these two levels of analysis: a neurobiological/neurochemical level and the psychological/behavioural level. A few years ago one of us proposed that the concept of ‘motivational salience’ may be one such linking variable (Kapur, Reference Kapur2003). The link between dopamine and the limbic system and the concept of salience is strong. But, this link is built mainly on animal studies using a variety of rather simple conditioning paradigms using rewarding and aversive stimuli. To make these concepts applicable to schizophrenia, an anthropomorphized notion of salience was proposed. Salience was defined as a process whereby objects and representations, through the process of association, come to be attention-grabbing and capture thought and behaviour. While this has served as a useful general heuristic – how does one test such a broad notion? Over the past few years several innovative groups has developed interesting and novel ways to do this and Roiser et al. provide one such interesting approach in this issue (Roiser et al. Reference Roiser, Stephan, den Ouden, Barnes, Friston and Joyce2008).
Roiser and colleagues used a probabilistic monetary task where adaptive and aberrant salience were operationalized as outcome measures, both having explicit and implicit components. They used medicated patients with schizophrenia and healthy matched controls and showed that the patients exhibited reduced adaptive salience. These were the hypothesized results because these were medicated patients and it was hypothesized that their treatment would have corrected their aberrant salience, but, dampened their adaptive salience. Interestingly however, Roiser et al. (Reference Roiser, Stephan, den Ouden, Barnes, Friston and Joyce2008) also found that within these treated patients, those with more positive symptoms showed increased aberrant salience compared to patients with less symptom load but also that this finding was mainly driven by the presence of delusions. Although these findings warrant further studies in unmedicated patients, using a probabilistic monetary task and making some sophisticated operationalizations the authors showed results that are predicted by the aberrant motivational salience model on the psychological level.
While Roiser et al. focused on a behavioural manifestation of salience, several recent studies have focused on the neurobiological level. The ventral striatum plays a central role in reward processing and it has been suggested that activations of the ventral striatum normally mediate motivational salience of environmental stimuli. A functional magnetic resonance imaging (fMRI) study by Juckel and collaborators (Juckel et al. Reference Juckel, Schlagenhauf, Koslowski, Wustenberg, Villringer, Knutson, Wrase and Heinz2006b) using a monetary incentive task showed that, compared to controls, unmedicated patients with schizophrenia displayed a reduced activation in the ventral striatum for cues predicting reward relative to a cue predicting no gain. This reduced activation was normalized when patients were treated with atypical medication but not with typical antipsychotics as evidenced by both a cross-sectional (Juckel et al. Reference Juckel, Schlagenhauf, Koslowski, Filonov, Wustenberg, Villringer, Knutson, Kienast, Gallinat, Wrase and Heinz2006a) and a longitudinal cross-over study (Schlagenhauf et al. Reference Schlagenhauf, Juckel, Koslowski, Kahnt, Knutson, Dembler, Kienast, Gallinat, Wrase and Heinz2008). The results suggest that the properties of the newer antipsychotics, such as lower striatal D2 blockade, modulation by serotonin and other systems, or their faster dissociation from the receptor, are beneficial for motivational salience which is in line with the normalized aberrant salience results of medicated patients. Interestingly, in the study of Roiser et al. 88% of the patients took second-generation drugs (Roiser et al. Reference Roiser, Stephan, den Ouden, Barnes, Friston and Joyce2008).
Using a different approach with fMRI, Murray et al. (Reference Murray, Corlett, Clark, Pessiglione, Blackwell, Honey, Jones, Bullmore, Robbins and Fletcher2008) undertook a study of first-episode psychosis patients, and found a disruption in reward prediction error among the patients. Abnormal activations in dopaminergic regions, such as ventral tegmental area/substantia nigra and the striatum were observed and the patients also had difficulties in discriminating between motivationally salient and neutral stimuli. Using an aversive conditioning paradigm with a loud noise as unconditioned stimulus in medicated patients, we found a similar abnormality in discriminating between motivational salient and neutral stimuli using both self-report data and autonomic measures (Jensen et al. Reference Jensen, Willeit, Zipursky, Savina, Smith, Menon, Crawley and Kapur2008). This was accompanied with deviant activation patterns in the ventral striatum suggesting that patients activated this region more towards neutral stimuli than healthy controls while they showed more similar activations to stimuli that the controls found motivationally salient, i.e. the conditioned stimulus. Both these studies (Jensen et al. Reference Jensen, Willeit, Zipursky, Savina, Smith, Menon, Crawley and Kapur2008; Murray et al. Reference Murray, Corlett, Clark, Pessiglione, Blackwell, Honey, Jones, Bullmore, Robbins and Fletcher2008) thus showed evidence of abnormal assignment of motivational salience and abnormal activation patterns in the hypothesized regions in patients with psychosis.
The behavioural and imaging data reported above are consistent with the idea that patients aberrantly assign motivational salience to neutral stimuli (Kapur, Reference Kapur2003), and this process may be one of the aberrations that predisposes them to psychosis. However, the different studies have used a slightly different interpretation and operationalization of ‘salience’. This is not surprising by itself, because concepts like ‘reward’ itself are operationalized in several different ways, and the concept of salience is loosely defined making such interpretations justified. The paper by Roiser et al. (Reference Roiser, Stephan, den Ouden, Barnes, Friston and Joyce2008), and several other recent ones are encouraging, but, the real challenge, as the title of this commentary suggests, is whether these ways of looking at psychosis will help us understand psychosis at a deeper level or deal with it more effectively. For that, more studies are needed: to replicate these initial results, to extend these studies to drug-naive patients, to examine the effect of medications in longitudinal studies and to look at the predictive value of these findings.
Declaration of Interest
None.